ADVANCING IMMUNOTHERAPY in ONCOLOGY, created in 2008 (United States), from 496 sister brands and 17477 competing brands. The ADVANCING IMMUNOTHERAPY in ONCOLOGY brand is owned by BRISTOL-MYERS SQUIBB COMPANY, a company listed in New York. The sector of ADVANCING IMMUNOTHERAPY in ONCOLOGY is Drug Manufacturers.

ADVANCING IMMUNOTHERAPY in ONCOLOGY is a brand of BRISTOL-MYERS SQUIBB COMPANY (BMY) Share price

Share price and profitability of the share BRISTOL-MYERS SQUIBB COMPANY (ADVANCING IMMUNOTHERAPY in ONCOLOGY)

Buy BRISTOL-MYERS SQUIBB COMPANY share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested USD 53.25

Portfolio valuation
BRISTOL-MYERS SQUIBB COMPANY (ADVANCING IMMUNOTHERAPY in ONCOLOGY) over 5 years* USD 59.90

Stock market history BRISTOL-MYERS SQUIBB COMPANY (ADVANCING IMMUNOTHERAPY in ONCOLOGY)